Search results
Results from the WOW.Com Content Network
The combination of bismuth subsalicylate and zinc salts for astringency with salol (phenyl salicylate) appears to have begun in the US in the early 20th century as a remedy for life-threatening diarrhea in infants with cholera. At first sold directly to physicians, it was first marketed as Bismosal in 1918. [20]
Bismuth subsalicylate is an antimicrobial agent of another drug class that can also be used to eradicate H. pylori for treating PUD. Agents for suppressing gastric acid secretion are proton-pump inhibitors (PPI), such as lansoprazole , pantoprazole , rabeprazole , omeprazole and esomeprazole .
Bismuth subsalicylate (BSS) has both antibacterial and anti-secretory actions that help with diarrhea. [1] Once in the gut, BSS gets broken down into bismuth and salicylic acid. [ 1 ] Bismuth produces other bismuth salts, which blocks the binding and proliferation of bacteria in stomach mucosal cells, leading to a decrease in inflammation in ...
While usually due to aspirin, other possible causes include oil of wintergreen and bismuth subsalicylate. [2] Excess doses can be either on purpose or accidental. [1] Small amounts of oil of wintergreen can be toxic. [2] Diagnosis is generally based on repeated blood tests measuring aspirin levels and blood gases. [1]
Bismuth subsalicylate should not be taken by those with aspirin allergy, kidney disease, or gout, nor concurrently with certain antibiotics such as the quinolones, and should not be taken continuously for more than three weeks. [medical citation needed] Some countries do not recommend it due to the risk of rare but serious side effects. [27]
Bismuth subsalicylate, a salt of bismuth and salicylic acid, "displays anti-inflammatory action (due to salicylic acid) and also acts as an antacid and mild antibiotic". [3] It is an active ingredient in stomach-relief aids such as Pepto-Bismol and some formulations of Kaopectate .
Results of the study indicate that Black women in the U.S., ages 66-75, saw the largest decrease in obesity between 2022-2023.
High-dose dual therapy has comparable efficacy with bismuth-containing quadruple therapy, with fewer adverse effects and higher compliance. [7] Although initial studies promisingly reported higher eradication rates, [3] there is no superiority compared to the other therapies except in the presence of clarithromycin resistant organisms.